Drugs / BIIB 722 CL
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02268604 | Oct 2010 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02224079 | Apr → Jun 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02227030 | Apr → Sep 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB 722 CL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02227030 ↗ |
| Route | Intravenous | “single intravenous (i.v.) doses of BIIB 722 CL” NCT02224079 ↗ |